R. L. Siegel, K. D. Miller, and A. Jemal, Cancer Statistics, CA Cancer J Clin, vol.67, pp.7-30, 2017.

L. Rahib, B. D. Smith, and R. Aizenberg, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, pp.2913-2921, 2014.

J. Ferlay, C. Partensky, and F. Bray, More deaths from pancreatic cancer than breast cancer in the EU by 2017, Acta Oncol, vol.55, pp.1158-1160, 2016.

T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, Pancreatic cancer, Lancet, vol.10039, pp.73-85, 2016.

T. Conroy, F. Desseigne, and M. Ychou, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1825, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

,

V. Hoff, D. D. Ervin, T. Arena, and F. P. , Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine, N Engl J Med, vol.369, pp.1691-1703, 2013.

,

M. Suker, B. R. Beumer, and E. Sadot, FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncol, vol.17, pp.801-810, 2016.

, , pp.172-180

P. Hammel, J. Lacy, and F. Portales, Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC), J Clin Oncol, vol.36, 2018.

L. Marthey, A. Sa-cunha, and J. F. Blanc, FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort, Ann Surg Oncol, vol.22, pp.295-301, 2015.

, NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version, vol.1, 2018.

, A randomized phase III trial comparing Folfirinox to gemcitabine in locally advanced pancreatic carcinoma (NEOPAN), 2019.

T. Conroy, P. Hammel, and M. Hebbar, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, vol.379, pp.2395-2406, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02281628

,

R. D. Peixoto, M. Ho, and D. J. Renouf, Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX, Am J Clin Oncol, vol.40, pp.507-511, 2017.

C. Vivaldi, C. Caparello, and G. Musettini, First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors, Int J Cancer, vol.139, pp.938-945, 2016.

H. Mahaseth, E. Brutcher, and J. Kauh, Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma, Pancreas, vol.42, pp.1311-1315, 2013.

J. Tabernero, E. G. Chiorean, and J. R. Infante, Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer, Oncologist, vol.20, pp.143-150, 2015.

,

D. Vernerey, F. Huguet, and A. Vienot, Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP), Br J Cancer, vol.115, pp.281-289, 2016.

D. Goldstein, V. Hoff, D. Chiorean, and E. , Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer, Ann Oncol, vol.28, issue.Suppl_3, pp.137-186, 2017.

S. F. Shariat, U. Capitanio, C. Jeldres, and P. I. Karakiewicz, Can nomograms be superior to other prediction tools?, BJU Int, vol.103, pp.492-495, 2009.

G. Masi, E. Vasile, and F. Loupakis, Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis, J Natl Cancer Inst, vol.103, pp.21-30, 2011.

E. D. Saad, J. R. Zalcberg, and J. Péron, Understanding and communicating measures of treatment effect on survival: can we do better?, J Natl Cancer Inst, vol.110, pp.232-240, 2018.

J. J. Fenton, P. R. Duberstein, and R. L. Kravitz, Impact of prognostic discussions on the patient-physician relationship: prospective cohort study, J Clin Oncol, vol.36, pp.225-230, 2018.

A. Vienot, G. Beinse, and C. Louvet, Overall survival prediction and usefulness of secondline chemotherapy in advanced pancreatic adenocarcinoma, J Natl Cancer Inst, vol.109, issue.10, 2017.

A. B. Mariotto, A. M. Noone, and N. Howlader, Cancer survival: an overview of measures, uses, and interpretation, J Natl Cancer Inst Monogr, vol.2014, p.97, 2014.

M. Reni, S. Zanon, and G. Balzano, Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma, Ann Oncol, vol.28, pp.2786-2792, 2017.

T. Kou, M. Kanai, and M. Yamamoto, Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy, Int J Clin Oncol, vol.21, pp.118-125, 2016.

,

C. Caparello, L. L. Meijer, and I. Garajova, FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer, World J Gastroenterol, vol.22, pp.6987-6700, 2016.

,

A. Fernández, M. Salgado, and A. García, Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study, BMC Cancer, vol.18, p.1185, 2018.

L. Ldh and . Dehydrogenase,

, NLR, neutrophil-to-lymphocyte ratio

, PLR, platelet-to-lymphocyte ratio